deltatrials
Completed PHASE1 NCT00817271

To Evaluate the Response to Glucagon During Hypoglycemia

A Randomised, Open, Two-Way Cross-Over, Phase I Study to Evaluate the Response to Glucagon Versus the Spontaneous Counter-Regulatory Response in T2DM Patients Treated With AZD1656 and Metformin During Hypoglycemia

Sponsor: AstraZeneca

Conditions Type 2 Diabetes
Interventions AZD1656 Glucagon
Updated 6 times since 2017 Last updated: May 6, 2009 Started: Feb 28, 2009 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

Listed as NCT00817271, this PHASE1 trial focuses on Type 2 Diabetes and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Chula Vista, United States